Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00
Provider: Sadif Analytics Prime
$10.00
Provider: Wright Reports
$426.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Deutsche Effecten Und Wechsel Beteiligungsgesellschaft AG announces positive results from emapticap pegol phase IIA study


Friday, 4 Apr 2014 06:05am EDT 

Deutsche Effecten Und Wechsel Beteiligungsgesellschaft AG:Announces Anti-CCL2 /MCP-1 Spiegelmer emapticap pegol (NOX-E36) shows beneficial and lasting effects on albuminuria and glycemic control.Emapticap pegol is Spiegelmer that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), pro-inflammatory chemokine that plays important role in diabetic kidney disease, most common single cause of chronic kidney failure and end-stage renal disease.Objective of this placebo-controlled multi-center international study was to evaluate efficacy, pharmacokinetics, safety and tolerability of treatment with emapticap pegol.Seventy-five type 2 diabetic patients with albuminuria on current standard of care to control hypertension, hyperglycemia and dyslipidemia were treated for 12 weeks with twice-weekly subcutaneous emapticap pegol or placebo.Emapticap pegol was found to be safe and well tolerated with no treatment-related serious adverse events.Results showed reductions in urinary albumin excretion and improved glycemic control.These effects were independent of hemodynamic changes and maintained after cessation of treatment, suggesting that emapticap pegol interferes with underlying pathophysiology of diabetic nephropathy. 

Company Quote